Vera Fridman

Vera Fridman

Auto-generated profile, based on publicly available information

Vera Fridman

University of Colorado Anschutz Medical Campus

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2014 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Open access
PDF file
VFV Fridman
V Fridman
BBB Bundy
B Bundy
MRM M Reilly
M M Reilly
DPDavide Pareyson
Davide Pareyson
CBC Bacon
C Bacon
MSMichael Shy
Michael Shy
Background The international Inherited Neuropathy Consortium (INC) was created with the goal of obtaining much needed natural history data for patients with Charcot-Marie-Tooth (CMT) disease. We analysed clinical and genetic data from patients in the INC to determine the distribution of CMT subtypes and the clinical impairment associated with them. Methods We analysed data from 1652 patients evaluated at 13 INC centres. The distribution of CMT subtypes and pathogenic genetic mutations were determined. The disease burden of all the mutations was assessed by the CMT Neuropathy Score (CMTNS) and CMT Examination Score (CMTES). Results 997 of the 1652 patients (60.4%) received a genetic diagnosis. The most common CMT subtypes were CMT1A/PMP22 duplication, CMT1X/GJB1 mutation, CMT2A/MFN2 mutation, CMT1B/MPZ mutation, and hereditary neuropathy with liability to pressure palsy/PMP22 deletion. These five subtypes of CMT accounted for 89.2% of all genetically confirmed mutations. Mean CMTNS for some but not all subtypes were similar to those previously reported. Conclusions Our findings confirm that large numbers of patients with a representative variety of CMT subtypes have been enrolled and that the frequency of achieving a molecular diagnosis and distribution of the CMT subtypes reflects those previously reported. Measures of severity are similar, though not identical, to results from smaller series. This study confirms that it is possible to assess patients in a uniform way between international centres, which is critical for the planned natural history study and future clinical trials. These data will provide a representative baseline for longitudinal studies of CMT. Clinical trial registration ID number NCT01193075.

9 January 2021 in Journal of Diabetes and its Complications
Verified
Journal Article
Closed access
VFV. Fridman
V. Fridman
SZS. Zarini
S. Zarini
SSS. Sillau
S. Sillau
KHK. Harrison
K. Harrison
BBB.C. Bergman
B.C. Bergman
BCB.C. Callaghan
B.C. Callaghan

1 October 2021 in Neurotherapeutics
Verified
Journal Article
Closed access
PDF file
VFVera Fridman
Vera Fridman
MSMario A. Saporta
Mario A. Saporta

11 February 2020 in Neurology
Verified
Journal Article
Closed access
PDF file
VFVera Fridman
Vera Fridman
SSStefan Sillau
Stefan Sillau
GAGyula Acsadi
Gyula Acsadi
CBChelsea Bacon
Chelsea Bacon
KDKimberly Dooley
Kimberly Dooley
T(the Inherited Neuropathies Consortium—Rare Diseases Clinical Research Network (INC-RDCRN)
the Inherited Neuropathies Consortium—Rare Diseases Clinical Research Network (INC-RDCRN)
Objective To evaluate the sensitivity of Rasch analysis-based, weighted Charcot-Marie-Tooth Neuropathy and Examination Scores (CMTNS-R and CMTES-R) to clinical progression in patients with Charcot-Marie-Tooth disease type 1A (CMT1A). Methods Patients with CMT1A from 18 sites of the Inherited Neuropathies Consortium were evaluated between 2009 and 2018. Weighted CMTNS and CMTES modified category responses were developed with Rasch analysis of the standard scores. Change from baseline for CMTNS-R and CMTES-R was estimated with longitudinal regression models. Results Baseline CMTNS-R and CMTES-R scores were available for 517 and 1,177 participants, respectively. Mean ± SD age of participants with available CMTES-R scores was 41 ± 18 (range 4–87) years, and 56% were female. Follow-up CMTES-R assessments at 1, 2, and 3 years were available for 377, 321, and 244 patients. A mixed regression model showed significant change in CMTES-R score at years 2 through 6 compared to baseline (mean change from baseline 0.59 points at 2 years, p = 0.0004, n = 321). Compared to the original CMTES, the CMTES-R revealed a 55% improvement in the standardized response mean (mean change/SD change) at 2 years (0.17 vs 0.11). Change in CMTES-R at 2 years was greatest in mildly to moderately affected patients (1.48-point mean change, 95% confidence interval 0.99–1.97, p < 0.0001, for baseline CMTES-R score 0–9). Conclusion The CMTES-R demonstrates change over time in patients with CMT1A and is more sensitive than the original CMTES. The CMTES-R was most sensitive to change in patients with mild to moderate baseline disease severity and failed to capture progression in patients with severe CMT1A. ClinicalTrials.gov identifier NCT01193075.

28 October 2022 in Annals of Neurology
Verified
Journal Article
Closed access
VFVera Fridman
Vera Fridman
SSStefan Sillau
Stefan Sillau
JBJacob Bockhorst
Jacob Bockhorst
KSKaitlin Smith
Kaitlin Smith
IMIsabella Moroni
Isabella Moroni
TNthe Inherited Neuropathies Consortium–Rare Diseases Clinical Research Network
the Inherited Neuropathies Consortium–Rare Diseases Clinical Research Network

7 August 2023 in Journal of the Peripheral Nervous System
Verified
Journal Article
Closed access
VFVera Fridman
Vera Fridman
SSStefan Sillau
Stefan Sillau
ARAlanna Ritchie
Alanna Ritchie
JBJacob Bockhorst
Jacob Bockhorst
Christina CoughlanChristina Coughlan
Christina Coughlan
JRJane E. B. Reusch
Jane E. B. Reusch